Related Experiment Video
Updated: Jun 18, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines
Edward I Cho1, Chunrui Tan, Gary K Koski
1Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Background:
The aim of the present study was to evaluate the therapeutic efficacy of dendritic cell (DC)-tumor fusion hybrids with Toll-like receptor (TLR) agonists.
Methods:
DC-tumor fusion hybrids were generated by electrofusion and injected into the inguinal lymph nodes of C57BL/6 mice with 3-day established pulmonary metastases. Paired TLR agonists polyinosine:polycytadilic acid [poly(I:C)] and cytosine-phosphate-guanine (CpG) were then injected intraperitoneally. Enzyme-linked immunosorbent assay (ELISA) was used to evaluate interleukin (IL)-12 production from the DC-tumor fusion hybrids in vitro.
Results:
Fusion + TLR agonists (60 metastases) had significantly fewer metastases than did the untreated control (262 metastases, p = .0001) and fusion alone (150 metastases, p = .02). ELISA showed that the DC-tumor fusion hybrids yielded 90 pg of IL-12 after TLR stimulation compared with 1610 pg from dendritic cells alone.
Conclusions:
CpG and poly(I:C) administered as a third signal with fusion hybrids as described significantly reduce melanoma metastasis compared with fusion hybrids alone. Fusion hybrids do not appear to be a significant source for IL-12 secretion.
Insights
Therapeutic cancer vaccines combining dendritic cell (DC)-tumor fusion hybrids with Toll-like receptor (TLR) agonists significantly reduced melanoma metastasis in mice. This combination therapy proved more effective than fusion hybrids alone.
Area of Science:
- Immunotherapy
- Cancer Research
- Cellular Biology
Background:
- Dendritic cell (DC)-tumor fusion hybrids are being investigated for cancer therapy.
- Toll-like receptor (TLR) agonists can modulate immune responses.
Purpose of the Study:
- To evaluate the therapeutic efficacy of combining DC-tumor fusion hybrids with TLR agonists.
- To assess the impact on melanoma metastasis in a murine model.
Main Methods:
- DC-tumor fusion hybrids were generated via electrofusion.
- Mice with pulmonary metastases received injections of fusion hybrids and TLR agonists (poly(I:C) and CpG).
- Interleukin (IL)-12 production was measured using ELISA.
Main Results:
- The combination of fusion hybrids and TLR agonists significantly reduced the number of metastases compared to controls and fusion hybrids alone.
- ELISA revealed limited IL-12 production from DC-tumor fusion hybrids post-TLR stimulation.
Conclusions:
- CpG and poly(I:C) as a third signal with fusion hybrids significantly reduce melanoma metastasis.
- DC-tumor fusion hybrids are not a primary source of IL-12 secretion in this context.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

